Start here if you're new
what it is
Edwards makes tools doctors use to repair and replace damaged heart valves.
how it gets paid
Last year Edwards Lifesci made $6.1B in revenue. Transcatheter Aortic Valve Replacement was the main engine at $4.6B, or 75% of sales.
why it's growing
Revenue grew 11.5% last year. Consensus had $0.58 versus $0.62. The source stack also shows $1.67 for the latest quarter.
what just happened
Edwards missed by $0.04 a share, even with $4.5B in quarterly sales.
At a glance
B++ balance sheet — above average — nothing keeping you up at night
100/100 earnings predictability — you can trust these numbers
32.4x trailing p/e — you're paying up for this one
14.0% return on capital — nothing to write home about
xvary composite: 62/100 — average
What they do
Edwards makes tools doctors use to repair and replace damaged heart valves.
Transcatheter aortic valve replacement (catheter-based valve swap) made 75% of 2024 revenue, versus 18% surgical and 7% mitral/tricuspid. That is one giant franchise and two smaller bets. For you, that means hospitals learn one system and keep coming back to the same playbook.
How they make money
$6.1B
annual revenue · their business grew +11.5% last year
Transcatheter Aortic Valve Replacement
$4.6B
Surgical Structural Heart
$1.1B
Transcatheter Mitral and Tricuspid Therapies
$0.4B
The products that matter
heart valve and repair devices
Structural Heart Devices
$6.1B · 100% of revenue
this is the whole business. If this category grows, EW grows. If it stalls, there is nowhere else to hide.
100% of sales
minimally invasive valve replacement
Transcatheter Aortic Valve Replacement
growth driver · +11.5% company growth
this is the product family most investors mean when they talk about the EW growth story. The page data does not break it out separately, so the honest read is that it sits inside the same $6.1B franchise.
where growth lives
traditional surgical valves and repair
Surgical Structural Heart
same franchise · no breakout here
this matters in the operating story, but the snapshot data does not split revenue or margin by product line. That means you should stay precise about what you know and honest about what you do not.
data thin
Key numbers
$84.27
share price
You are paying $84.27 for a stock with only $92 of 18-month upside on the table.
32.4x
price on past profit
That means $32.40 for each $1 of past profit, so the market wants steady execution.
20.8%
operating margin
For every $100 of sales, $20.80 stays after operating costs.
14.0%
capital return
The business turns invested money into profit at 14.0%, which is decent, not heroic.
Financial health
B++
strength
- balance sheet grade B++ — above average financial health
- risk rank 3 — safer than 50% of stocks
- price stability 55 / 100
- long-term debt $598M (1% of capital)
- net profit margin 27.3% — keeps 27 cents of every dollar in revenue
- return on equity 14% — $0.14 profit for every $1 investors have put in
B++ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in EW 3 years ago → it's now worth $10,770.
The index would have given you $14,770.
source: institutional data · total return
What just happened
missed estimates
Edwards missed by $0.04 a share, even with $4.5B in quarterly sales.
Consensus had $0.58 versus $0.62. The source stack also shows $1.67 for the latest quarter, so the dataset disagrees on EPS. Revenue still jumped 190% vs. prior year, and gross margin held at 78.0%.
$4.5B
revenue
$0.58
eps
78.0%
gross margin
the miss that mattered
The $0.04 miss mattered because this stock already trades at 32.4x earnings, so small slips still get noticed.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the main risk is simple: when 100% of revenue comes from one category and the stock trades at 32.4x earnings, ordinary slowing can become a valuation event.
med
32.4x earnings leaves less room for normal disappointment
the stock trades at a premium while return on capital is 13.5% and the composite score is 62/100. If growth stays good instead of looking great, investors can decide the multiple is the problem.
the pressure point is right there in the math: a premium stock expected to earn $2.90 per share this year.
med
all $6.1B of revenue comes from one franchise
that focus is part of the edge, but it is also concentration risk. EW is not offsetting a slower device cycle with another major division. Structural heart is the whole movie.
if procedure demand, adoption, or product mix weakens, it touches 100% of reported revenue.
med
institutional demand has been slightly negative
537 buyers versus 540 sellers is not dramatic. It still means the biggest pools of capital have been net sellers for two straight quarters while the stock sits near the top of its $66–$87 range.
when a premium stock loses sponsorship, valuation support usually gets thinner before fundamentals do.
med
the stock has been paid for predictability, so any wobble gets noticed fast
EW scores 100/100 on earnings predictability. That is a strength until it is not. Premium names that train investors to expect clean quarters tend to get punished harder when the numbers stop landing on schedule.
if quarterly revenue drops below the recent $1.6B pace or the path to $7B gets less believable, the market will likely reprice first and debate nuance later.
you are not taking balance-sheet risk here. You are taking concentration risk and price risk in a business the market already respects.
source: institutional data · regulatory filings · risk analysis
Pay attention to
earnings
the next print has to keep the premium alive
watch for another quarter near the recent $1.6B revenue level and for EPS to keep building toward the current $2.90 full-year estimate.
metric
the path from $6.1B to the $7B revenue estimate
that gap is the street's growth assumption in one line. If management stops closing it, the valuation argument gets a lot weaker.
trend
whether 11.5% growth still outruns valuation fatigue
EW can grow and still disappoint the stock if growth starts to look merely solid instead of premium-worthy.
risk
institutional flow after 537 buyers versus 540 sellers
slight selling is not a thesis by itself. It matters because premium stocks usually look healthier when big money is adding, not trimming.
Analyst rankings
short-term outlook
average
momentum score 3 — in human-speak, analysts do not see a near-term edge here.
risk profile
average
stability score 3 — this sits in the middle of the pack on risk, not in the bunker-stock category.
chart momentum
top 20%
technical score 2 — the chart looks stronger than the valuation debate does right now.
earnings predictability
100 / 100
management's numbers usually land close to the script. That is a real asset when the market is charging 32.4x earnings.
source: institutional data
Institutional activity
institutions have been net selling for 2 consecutive quarters — 537 buyers vs. 540 sellers in 3q2025. total institutional holdings: 0.5B shares. net selling for 2 quarters.
source: institutional data
Price targets
3-5 year target range
$69
$114
$84
current price
$92
target midpoint · +9% from current · 3-5yr high: $165 (+95% · 18% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive